ES2190484T3 - Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano. - Google Patents

Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano.

Info

Publication number
ES2190484T3
ES2190484T3 ES96942362T ES96942362T ES2190484T3 ES 2190484 T3 ES2190484 T3 ES 2190484T3 ES 96942362 T ES96942362 T ES 96942362T ES 96942362 T ES96942362 T ES 96942362T ES 2190484 T3 ES2190484 T3 ES 2190484T3
Authority
ES
Spain
Prior art keywords
diagnosis
procedure
plano
carcinomas
epithelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96942362T
Other languages
English (en)
Inventor
Karl-Heinz Heider
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Karlsruher Institut fuer Technologie KIT
Original Assignee
Boehringer Ingelheim International GmbH
Forschungszentrum Karlsruhe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim International GmbH, Forschungszentrum Karlsruhe GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2190484T3 publication Critical patent/ES2190484T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROCEDIMIENTO PARA DIAGNOSIS Y TRATAMIENTO DE EPITELIOMAS, QUE DESCANSA EN LA EXPRESION DE LA VARIANTE EXON V6 DEL GEN CD44 COMO DIANA MOLECULAR. EN UNA REALIZACION PREFERIDA, PARA ESTE FIN SE UTILIZAN ANTICUERPOS MOLECULARES ESPECIFICOS DE V6, EN PARTICULAR EL ANTICUERPO MONOCLONAL BIWA-1 (VFF-18).
ES96942362T 1995-12-06 1996-12-05 Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano. Expired - Lifetime ES2190484T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17

Publications (1)

Publication Number Publication Date
ES2190484T3 true ES2190484T3 (es) 2003-08-01

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96942362T Expired - Lifetime ES2190484T3 (es) 1995-12-06 1996-12-05 Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano.

Country Status (25)

Country Link
EP (1) EP0865609B1 (es)
JP (1) JP2000502067A (es)
KR (1) KR100473824B1 (es)
CN (1) CN1151377C (es)
AR (1) AR004360A1 (es)
AT (1) ATE235056T1 (es)
AU (1) AU726704B2 (es)
BG (1) BG62985B1 (es)
BR (1) BR9611901A (es)
CA (1) CA2239709A1 (es)
CO (1) CO4520233A1 (es)
CZ (1) CZ174198A3 (es)
DE (1) DE59610248D1 (es)
DK (1) DK0865609T3 (es)
EE (1) EE03783B1 (es)
ES (1) ES2190484T3 (es)
MX (1) MX9804459A (es)
NO (1) NO319903B1 (es)
NZ (1) NZ324314A (es)
PL (1) PL184521B1 (es)
PT (1) PT865609E (es)
SK (1) SK284378B6 (es)
TR (1) TR199801027T2 (es)
UY (1) UY24389A1 (es)
WO (1) WO1997021104A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
AR036154A1 (es) * 2001-05-18 2004-08-18 Boehringer Ingelheim Pharma Anticuerpos especificos de cd44v6.
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
MA34010B1 (fr) * 2010-02-04 2013-02-01 Hoffmann La Roche Anticorps monoclonal anti-cd44 destiné à être utilisé pour traiter le carcinome à cellules squameuses de la tête et du cou
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODY AND USES THEREOF
CN119451984A (zh) 2022-05-25 2025-02-14 阿基拉姆治疗有限公司 抗cd44v6抗体及其用于治疗cd44v6过表达癌症的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159953T1 (de) * 1993-06-18 1997-11-15 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
EP0767379A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Kolonkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
BR9611901A (pt) 1999-03-02
NO319903B1 (no) 2005-09-26
CN1151377C (zh) 2004-05-26
CN1207811A (zh) 1999-02-10
WO1997021104A1 (de) 1997-06-12
PL327066A1 (en) 1998-11-23
NO982588D0 (no) 1998-06-05
PL184521B1 (pl) 2002-11-29
TR199801027T2 (xx) 1998-10-21
PT865609E (pt) 2003-08-29
BG102513A (en) 1999-02-26
BG62985B1 (bg) 2000-12-29
EP0865609A1 (de) 1998-09-23
ATE235056T1 (de) 2003-04-15
CO4520233A1 (es) 1997-10-15
DE59610248D1 (de) 2003-04-24
NO982588L (no) 1998-08-05
CZ174198A3 (cs) 1999-02-17
MX9804459A (es) 1998-09-30
DK0865609T3 (da) 2003-06-23
KR19990071952A (ko) 1999-09-27
EP0865609B1 (de) 2003-03-19
HK1011560A1 (en) 1999-07-16
UY24389A1 (es) 2001-10-25
KR100473824B1 (ko) 2005-09-30
EE03783B1 (et) 2002-06-17
AR004360A1 (es) 1998-11-04
AU726704B2 (en) 2000-11-16
CA2239709A1 (en) 1997-06-12
SK73698A3 (en) 1999-01-11
AU1177397A (en) 1997-06-27
JP2000502067A (ja) 2000-02-22
SK284378B6 (sk) 2005-02-04
NZ324314A (en) 2000-02-28
EE9800164A (et) 1998-12-15

Similar Documents

Publication Publication Date Title
ES2190484T3 (es) Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
ES520692A0 (es) Un procedimiento de preparacion de conjugados inmunoenzimaticos.
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
PE20050712A1 (es) Anticuerpos rg1
ES2151603T3 (es) Anticuerpo monoclonal contra cd44v6.
CY1117764T1 (el) Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
SE7512192L (sv) Cancerantigen, cancerterapi och cancerdiagnostikum
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
MXPA01003344A (es) Composiciones y metodos para inmunoterapia especifica de wt1.
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
MY154009A (en) Anti-alpha v beta 6 antibodies
DE69006135D1 (de) Einsatzrohr für die Reparatur von Rohrleitungen.
ATE424560T1 (de) Marker für neuromyelitis optica
DE60331638D1 (de) Keratin-netzwerke enthaltende wundverbände für gewebedefekte
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
CO4940435A1 (es) Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6- (ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol o un solvato del mismo
DK1173766T3 (da) Isoform af tenascin-C som markör for neoplasier
FI974018A0 (fi) Ihmisen 2 integriini -alayksikkö
SU512761A1 (ru) Хирургический инструмент дл ультразвукового разделени биологических тканей